New monkeypox shot technique to get emergency US approval to extend supply

The US supply of the vaccine Jynneos, developed by Danish firm Bavarian Nordic, cannot meet current demand. However, a new dose-saving method might mean more people can get shots without sacrificing protection.

Photo: Bavarian Nordic / PR

US health officials are issuing emergency clearance to a technique for extending the supply of monkeypox vaccine made by Bavarian Nordic A/S amid ongoing shortages.

The action will allow the US Food and Drug Administration (FDA) to “exercise additional authorities that may increase availability of vaccines to prevent monkeypox while continuing to ensure the vaccine meets high standards for safety, effectiveness and manufacturing quality,” Department of Health and Human Services Secretary Xavier Becerra said in a statement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs